Royalty Report: Drugs, Disease, Therapeutic – Collection: 29259


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29259

License Grant
The University hereby grants Sponsor an exclusive option to negotiate an exclusive worldwide License for University's right in University Invention(s) or Joint Invention(s). The Sponsor may exercise this Option at any time on or prior to sixty (60) days from disclosure of the Invention to the Sponsor.
License Property
The parties will enter into a collaborative research Agreement with the laboratory of Dr. Thomas Scanlan to synthesize and test small molecules that may be useful in the treatment of human disease conditions involving chronic inflammation such as rheumatoid arthritis, asthma, and inflammatory bowel syndrome.

IPSCIO Record ID: 28716

License Grant
Licensor is willing to grant certain rights to patents and technology that may result from the research collaboration.

Licensor and Licensee are each pursuing various aspects of research in the field of Apheresis Selective Depletion of Small Reactive Molecules and Pathogens that Involves a Novel Treatment of the Pathophysiologic Basis of Diseases such as Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes.

License Property
Technology involved is in the area of sequential-dialysis.  Intellectual property developed as a result of the projects will be owned jointly by the Licensor and Licensee.

IPSCIO Record ID: 341530

License Grant
Under the terms of the new arrangement, Belgium Licensee will assume all development, manufacturing, commercialization and certain other rights for filgotinib in Europe.
License Property
Filgotinib preferential JAK1 inhibitor with a potential best-in-class product profile (Jyseleca). Janus kinases (JAK) are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in RA. Filgotinib is a preferential JAK1 inhibitor. Jyseleca® is the brand name for filgotinib
Field of Use
Field of Use is for the treatment of IBD (Inflammatory Bowel Disease), CD (Crohns Disease), UC (Ulcerative Colitis) and potentially other inflammatory diseases such as RA (Rheumatiod arthritus).

Inflammatory Bowel Disease (IBD) This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel.

Crohn’s disease (CD) An IBD involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel.

Ulcerative colitis (UC) An IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract).

Rheumatoid arthritis (RA) A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability.

Inflammatory diseases is a large, unrelated group of disorders associated with abnormalities in inflammation.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.